Arcus Biosciences, Inc. Share Price & Technical Analysis
RCUS · $23.43 (-1.84%)
Healthcare / Biotechnology
$23.43
-1.84%
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-9% return in May, 5% avg return in past 3 year May month.
-2% return in 2026, 17% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -12% | -3% | 5% | 15% | -9% | – | – | – | – | – | – | – | -2% |
| 25 | -15% | -13% | -28% | 13% | 2% | -12% | 12% | 18% | 28% | 47% | 31% | -7% | 76% |
| 24 | -21% | 20% | -2% | -19% | -1% | -4% | 8% | 5% | -9% | 1% | 0% | -3% | -25% |
| 23 | 4% | -15% | -1% | -2% | 15% | 1% | -2% | 5% | -14% | -12% | -4% | 28% | 1% |
| 22 | -24% | 20% | -16% | -23% | -21% | 32% | 4% | -8% | 11% | -4% | 36% | -41% | -34% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.10B
P/E ratio
—
52W high
$28.72
52W low
$7.91
Volume
3,83,327
Beta
0.87
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Arcus Biosciences, Inc. share price today?
- Arcus Biosciences, Inc. (RCUS) last traded around $23.43 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RCUS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RCUS. Download the app for real-time alerts.
- How can I analyze Arcus Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.